$0.33
-0.01 (-2.21%)
Open$0.35
Previous Close$0.34
Day High$0.35
Day Low$0.33
52W High$2.57
52W Low$0.29
Volume—
Avg Volume914.3K
Market Cap23.04M
P/E Ratio—
EPS$-0.91
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+3,325.6% upside
Current
$0.33
$0.33
Target
$11.39
$11.39
$7.11
$11.39 avg
$14.81
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.40M | 5.91M | 16.16M |
| Net Income | -67,772,477 | -66,763,604 | -2,032,977 |
| Profit Margin | -1,256.8% | -1,194.0% | -12.6% |
| EBITDA | -69,433,069 | -72,199,447 | -2,828,117 |
| Free Cash Flow | — | — | -1,769,464 |
| Rev Growth | -8.6% | -8.6% | -2.0% |
| Debt/Equity | 0.26 | 0.26 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.35 | -1.10% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $419.87 | +0.42% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.65 | -1.02% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $525.69 | -0.38% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | +0.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $252.46 | -1.14% | 41.4 | 33.44B |